Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aldeyra Therapeutics, Inc. (ALDX : NSDQ)

• Company Description    Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $4.80 Daily Weekly Monthly 20 Day Moving Average: 1,083,075 shares Shares Outstanding: 59.90 (millions) Market Capitalization: $287.50 (millions) Beta: 0.90 52 Week High: $7.20 52 Week Low: $1.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 63.82% 57.69% 12 Week 119.18% 84.36% Year To Date -3.81% -9.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 131 HARTWELL AVENUE SUITE 320 - LEXINGTON,MA 02421 USA ph: 781-761-4904 fax: 781-270-0630 investorrelations@aldeyra.com http://www.aldeyra.com

• General Corporate Information    Officers Todd C. Brady - President; Chief Executive Officer and Director Richard H. Douglas - Chairman Ben Bronstein - Director Martin J. Joyce - Director Nancy Miller-Rich - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 01438T106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 59.90 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $287.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.90 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -21.43% vs. Previous Quarter: 37.04% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -72.58 12/31/24 - -60.74 ROA 06/30/25 - - 03/31/25 - -52.32 12/31/24 - -45.66 Current Ratio 06/30/25 - - 03/31/25 - 6.49 12/31/24 - 5.59 Quick Ratio 06/30/25 - - 03/31/25 - 6.49 12/31/24 - 5.59 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.06 12/31/24 - 1.19 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.24 12/31/24 - 0.21 Debt-to-Capital 06/30/25 - - 03/31/25 - 19.19 12/31/24 - 17.44

Powered by Zacks Investment Research ©